Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 3/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.47 |
| ▸ | HTR2C | P28335 | 3/20 | 0.47 |
| ▸ | CDK1 | P06493 | 3/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.43 |
| ▸ | CDK2 | P24941 | 3/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20303710 | 0.98 | P2RX4 (0.49) | P2RX4MCHR1HTR2CCDK1CCNB1 | |
| SCHEMBL11160163 | 0.92 | RIPK1 (0.50) | P2RX4HTR2CRIPK1 | |
| Trifluoroacetic Acid SCHEMBL20303811 | 0.89 | P2RX4 (0.46) | P2RX4MCHR1HTR2CFAAHCNR1 | |
| SCHEMBL28904257 | 0.85 | P2RX4 (0.54) | P2RX4MCHR1HTR2CRIPK1 | |
| SCHEMBL4873733 | 0.78 | PARP10 (0.53) | P2RX4CDK1CCNB1CDK2CCNA2 | |
| SCHEMBL10561536 | 0.77 | ALDH1A1 (0.57) | P2RX4 | |
| SCHEMBL3990024 | 0.76 | RIPK1 (0.54) | HTR2CCNR2RIPK1 | |
| SCHEMBL79139 | 0.76 | GAA (0.50) | MCHR1HTR2CFAAHCNR1CNR2 | |
| SCHEMBL9370895 | 0.76 | MCHR1 (0.56) | MCHR1HTR2CCDK2FAAHCNR1 | |
| SCHEMBL5777914 | 0.76 | LMNA (0.50) | MCHR1HTR2CFAAHCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440527-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | Topo Target A/S (DK) | 2012-04-18 | — | — | EP | claimed |
| WO-2010142735-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | TOPOTARGET A/S (DK) | 2010-12-16 | — | — | WO | claimed |
| US-20190322676-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARM INC (US) | 2019-10-24 | — | — | US | disclosed |
| WO-2018118838-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322676-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | UGCG, MAN2B1, GBA1 | P2RX4 4855/4885MCHR1 2717/4885HTR2C 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.